NordiQC EQA Data and Observations for PD-L1 Biomarker Testing By Søren Nielsen, Director, NordiQC Immune-checkpoint inhibitors targeting PD-1 or PD-L1 as pembrolizumab, nivolumab, durvalumab and atezolizumab have since 2016 been approved for multiple cancers as lung carcinoma, urothelial carcinoma, melanoma, breast carcinoma and many other solid cancers. At present Immunohistochemistry (IHC) for PD-L1 expression is read more…
Monthly Archives: April 2021
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path) Fenizia, F., Wolstenholme, N., Fairley, J.A. et al. Virchows Arch (2021). You can access the article here: https://rdcu.be/ciMl7 Abstract While tumour mutation burden (TMB) is emerging as a possible biomarker for immune-checkpoint inhibitors (ICI), methods for testing have not been standardised as yet. read more…